Non-alcoholic Steatohepatitis
Conditions
Keywords
Non-alcoholic steatohepatitis (NASH), Liver disease
Brief summary
This is a Phase I Randomised Single-blind Placebo-controlled Study to Assess the Safety, Tolerability, and Pharmacokinetics of AZD9550 Following Single Ascending Dose Administration to Healthy Participants.
Detailed description
This study will be a Phase I, First-In-Human (FIH), randomised, single-blind, placebo-controlled, single ascending dose (SAD), sequential group study in healthy male and female participants of non- childbearing potential performed at a single study centre. The study consists of 3 parts: * Part A: SAD (up to 5 dose levels) of AZD9550 administered subcutaneous (SC) in healthy participants. * Part B: 1 dose level of AZD9550 administered SC in healthy participants of Japanese descent. * Part C: 1 dose level of AZD9550 administered intravenous (IV) in healthy participants. The study will comprise of: * A Screening Period of maximum 28 days. * A Treatment Period during which participants will be resident at the Clinical Unit from 2 days before (Day -2) investigational medicinal product (IMP\]) administration (Day 1) until at least 7 days (168 hours; Day 8) after IMP administration. * Weekly out-clinic visits on Days 15, 22, 29, and 36. * A Follow-up Visit 6 weeks (Day 43) after the IMP dose.
Interventions
DRUGAZD9550
Participants will be administered AZD9550 subcutaneously.
DRUGPlacebo
Participants will be administered matching volumes of placebo subcutaneously or intravenously.
Sponsors
Parexel
AstraZeneca
Study design
Allocation
RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Masking description
The participant and the Clinical Unit staff will remain blinded during the dosing phase of the study.
Intervention model description
Placebo-control
Eligibility
Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
Yes
Inclusion criteria
* Provision of signed and dated, written informed consent prior to any study-specific procedures. * Healthy male and female participants aged 18 to 55 years. * Females must have a negative pregnancy test at the Screening Visit and on admission to the Clinical Unit, must not be lactating, and must be of non childbearing potential, confirmed at the Screening Visit by fulfilling one of the following criteria: 1. Postmenopausal defined as amenorrhoea for at least 12 months or more following cessation of all exogenous hormonal treatments and Follicle stimulating hormone (FSH) levels in the postmenopausal range. 2. Documentation of irreversible surgical sterilisation by hysterectomy, bilateral oophorectomy or bilateral salpingectomy but not tubal ligation. * Have a Body mass index (BMI) between 18 and 30 kg/m\^2 inclusive and weigh at least 50 kg and no more than 100 kg inclusive at Screening and admission.
Exclusion criteria
* History of any clinically important disease or disorder which, in the opinion of the Investigator, may either put the participant at risk because of participation in the study, or influence the results or the participant's ability to participate in the study. * History or presence of gastrointestinal, hepatic or renal disease or any other condition known to interfere with absorption, distribution, metabolism or excretion of drugs. * Any clinically important illness, medical/surgical procedure or trauma within 4 weeks of the first administration of Investigational medicinal product (IMP). * Any laboratory values with the following deviations at Screening and admission: 1. Alanine aminotransferase \> Upper limit of normal (ULN) 2. Aspartate aminotransferase \> ULN 3. eGFR \< 60 mL/min/1.73m2 (to be calculated using CKD-EPI formula) 4. White blood cell count \< LLN 5. Hemoglobin \< LLN 6. Neutrophil Count \<1.5 × 10\*9/L * Any clinically important abnormalities in clinical chemistry, haematology or urinalysis results other than those described under exclusion criterion number 4, as judged by the Investigator. * Any positive result at Screening for serum hepatitis B surface antigen, hepatitis C antibody and Human immunodeficiency virus (HIV). * Abnormal vital signs, after 10 minutes supine rest at Screening. * Any clinically important abnormalities in rhythm, conduction or morphology of the resting Electrocardiogram (ECG) and any clinically important abnormalities in the 12 lead ECG that may interfere with the interpretation of QTc interval changes, including abnormal ST T wave morphology, particularly in the protocol defined primary lead or left ventricular hypertrophy. * History of severe allergy/hypersensitivity or ongoing clinically important allergy/hypersensitivity, as judged by the Investigator or history of hypersensitivity to drugs with a similar chemical structure or class to AZD9550. * Plasma donation within one month of the Screening Visit or any blood donation/blood loss \> 500 mL during the 3 months prior to the Screening Visit. * Has received another new chemical entity (defined as a compound which has not been approved for marketing) within 3 months of the first administration of IMP in this study. The period of exclusion begins 3 months after the final dose or one month after the last visit whichever is the longest. Note: participants consented and screened, but not randomised in this study or a previous Phase I study, are not excluded. * Judgment by the Investigator that the participant should not participate in the study if they have any ongoing or recent (ie, during the Screening period) minor medical complaints that may interfere with the interpretation of study data or are considered unlikely to comply with study procedures, restrictions and requirements. * Participants with a medical history of Medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome (MEN 2), or a baseline serum calcitonin at or above 50 ng/L. * Any condition that would have interfered with the evaluation of the IMP or interpretation of participant safety or study results. * Participants who are unable to consume in full the MMTT (Mixed meal tolerance test - Ensure Plus 200 mL). * Participants with a medical history of MTC (Medullary thyroid carcinoma) or MEN 2 (multiple endocrine neoplasia syndrome), or a baseline serum calcitonin at or above 50 ng/L.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Adverse Events (AEs) and Serious Adverse Events (SAEs) | Throughout the study (up to 6 months) | The safety and tolerability of AZD9550 following SC administration of single ascending doses to healthy participants, SC administration of a single dose to Japanese participants, and IV administration of a single dose to healthy participants will be assessed. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Area under concentration time curve from time 0 to infinity (AUCinf) | Day 1 until Day 43 (follow-up visit) | The AUCinf of AZD9550 following SC administration of single ascending doses to healthy participants, SC administration of a single dose to Japanese participants, and IV administration of a single dose to healthy participants will be assessed. |
| Area under concentration-time curve from time 0 to the last quantifiable concentration (AUClast) | Day 1 until Day 43 (follow-up visit) | The AUClast of AZD9550 following SC administration of single ascending doses to healthy participants, SC administration of a single dose to Japanese participants, and IV administration of a single dose to healthy participants will be assessed. |
| Maximum observed concentration (Cmax) | Day 1 until Day 43 (follow-up visit) | The Cmax of AZD9550 following SC administration of single ascending doses to healthy participants, SC administration of a single dose to Japanese participants, and IV administration of a single dose to healthy participants will be assessed. |
| Incidence of Anti-Drug Antibodies (ADAs) | Day 1 until Day 43 (follow-up visit) | The immunogenicity of AZD9550 following SC and/or IV administration of AZD9550 will be assessed. |
Countries
United Kingdom
Outcome results
None listed